Cutler Group LP Ardelyx, Inc. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	BUY	$3.23 - $4.95 $998 - $1,529	309 New	309 $1,000
Q4 2022 Feb 07, 2023	BUY	$1.22 - $2.85 $1,220 - $2,850	1,000 New	1,000 $2,000
Q2 2022 Aug 04, 2022	BUY	$0.51 - $1.17 $1,836 - $4,212	3,600 Added 225.0%	5,200 $3,000
Q1 2022 Apr 14, 2022	SELL	$0.65 - $1.18 $10,024 - $18,197	-15,422 Reduced 90.6%	1,600 $1,000
Q4 2021 Jan 18, 2022	SELL	$0.86 - $1.7 $13,805 - $27,290	-16,053 Reduced 48.54%	17,022 $18,000
Q3 2021 Oct 26, 2021	BUY	$1.27 - $8.17 $28,346 - $182,354	22,320 Added 207.53%	33,075 $43,000
Q2 2021 Jul 19, 2021	BUY	$6.55 - $8.98 $69,790 - $95,681	10,655 Added 10655.0%	10,755 $81,000
Q3 2020 Oct 27, 2020	BUY	$5.25 - $7.08 $525 - $708	100 New	100 $0
Q3 2018 Nov 07, 2018	SELL	$3.75 - $4.65 $375 - $465	-100 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$5.05 - $7.9 $17,170 - $26,860	-3,400 Reduced 97.14%	100 $0
Q3 2017 Oct 17, 2017	BUY	$4.35 - $5.7 $15,224 - $19,950	3,500	3,500 $19,000

214

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $854M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.